171 Detection of non-metastatic non-small cell lung cancer in urine .838 LUAD (n=27) LUSC (n=16) NOS (n=1) 0 1 2 3 5 LUAD (n=27) LUSC (n=16) NOS (n=1) .264 LUAD (n=27) LUSC (n=16) NOS (n=1) .886 .444 I (n=28) II (n=4) III (n=12) 0 1 2 3 5 I (n=28) II (n=4) III (n=12) 0.0495 I (n=28) II (n=4) III (n=12) .844 CDO1 SOX17 TAC1 CDO1 SOX17 TAC1 A B Methylation level (sqrt Ct ratio) Methylation level (sqrt Ct ratio) Supplementary Figure 2: Methylation levels of NSCLC patients per cancer stage and histological subtype. Methylation levels of markers CDO1, SOX17, and TAC1 in the urine supernatant of surgical NSCLC patients, stratified by cancer stage (A) and histological subtype (B). Data is depicted as the median with an interquartile range of square root transformed Ct ratios. Each symbol represents a single case. A P-value of <.05 was considered statistically significant. Statistical testing was not performed for NOS due to the low number of patients in this group (n=1). LUAD = lung adenocarcinoma, LUSC = lung squamous cell carcinoma, NOS = carcinoma not otherwise specified. 6
RkJQdWJsaXNoZXIy MjY0ODMw